Samuel Asanad, MD
Ophthalmology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 7 years
- Graduated 2019
Offices
5 locations · Retina Vitreous Associates Medical Group · USC Care Medical Group Inc
Hospitals listed: Keck Hospital of USC · Los Angeles General Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Asanad’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A195274 · Current
Licensed to practise in California · since 2024 · expires 2028-06-30 · David Geffen School of Medicine at UCLA.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Keck Hospital of USCLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of University of Southern California, which runs 4 hospitalsHome of USC Norris Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.79 (0.6 to 0.97), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.33 (2.15 to 8.51) · 2,872 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.25 (0.38 to 4.13) · 2,875 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.153, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.565, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.644, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.143, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.287, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 992 cases, Jan 2024 – Dec 2024
- Los Angeles General Medical CenterLos Angeles, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Los Angeles County Department of Health Services, which runs 4 hospitalsPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.404, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.115, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.151, Oct 2024 – Sep 2025
See every measure and the patient survey for Keck Hospital of USC
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.6 to 0.97) | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.33 (2.15 to 8.51) · 2,872 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.25 (0.38 to 4.13) · 2,875 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.153 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.565 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.644 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.143 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.287 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 992 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.47 to 1.79) · 3,513 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 178.09 (145.37 to 210.81) · 267 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 134 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.9 · 61 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 2,086 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0.03 to 0.39) · 6,677 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.12 to 0.48) · 7,784 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.38 (2.05 to 4.71) · 4,593 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.02 (0.97 to 3.08) · 2,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.52 (0.5 to 2.55) · 3,742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.61 (1.35 to 3.87) · 1,628 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.17 to 1.02) · 5,896 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 128 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.928 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 112 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 139 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11.5 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.7 · 167 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -34.3 · 42 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.2 (2.8 to 6.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.7 (7.8 to 14.3) · 103 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.3 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.9 to 14.5) · 1,774 cases | No different | Jan 2022 – Dec 2024 |
What patients said (744 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Los Angeles General Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.115 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.151 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.16 (0.15 to 2.17) · 711 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.61 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.4 (120.6 to 222.19) · 58 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 39 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 157 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.9 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 141 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,031 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,814 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 4,165 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.1 (1.83 to 6.37) · 740 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 252 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.58 to 3.68) · 683 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.88 (0 to 16.03) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.15 (3.29 to 11.02) · 256 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.31 (0.83 to 3.8) · 143 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0 to 1.08) · 3,097 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.191 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 58 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.2 · 280 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.5 · 217 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.7 · 164 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 208 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.1 to 8.3) · 194 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.5 (8.5 to 15.3) · 194 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 107 cases | None | Jul 2023 – Jun 2025 |
What patients said (651 patients answered, 13% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Drugs they prescribed that Part D paid
$6,589
Pharmacies billed $6,589 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
53 generic and fewer than 11 brand-name prescriptions · $6,589 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 12 | $436 | $36 |
| Latanoprost | 15 | $195 | $13 |
Year by year
| 2024 | 93 | 41 | None | None | $6,589 |
| 2023 | 141 | 56 | 0% (0) | 39% | $17,341 |
| 2022 | 198 | 69 | 0% (0) | 46% | $34,714 |
| 2021 | 114 | 39 | None | None | $11,318 |
| 2020 | 20 | None | 0% (0) | 0% | $454 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Brimonidine | 17 | $1,921 | $113 |
| Latanoprost | 38 | $674 | $18 |
| Dorzolamide-Timolol | 21 | $591 | $28 |
2022: 6 drugs
| Lumigan | 27 | $9,910 | $367 |
| Rocklatan | 16 | $8,208 | $513 |
| Brimonidine | 16 | $1,965 | $123 |
| Latanoprost | 35 | $551 | $16 |
| Dorzolamide-Timolol | 21 | $461 | $22 |
| Erythromycin | 15 | $198 | $13 |
Money from drug and device companies
$921 in 2025
| 2025 | 4 | 17 | None | $921 |
| 2024 | 3 | 5 | None | $324 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Ozurdex | $333 | 10 payments
|
| Apellis Pharmaceuticals | Syfovre | $266 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $205 | 3 payments
|
| Alcon Vision | Hydrus Microstent | $116 | 2 payments
|
See all 17 published payments
| Abbvie | Meals · 2025-11-27 | Ozurdex | $32 |
| Alcon Vision | Meals · 2025-11-14 | Unity | $47 |
| Regeneron Healthcare Solutions | Meals · 2025-11-12 | Eylea Hd | $107 |
| Abbvie | Meals · 2025-11-08 | Ozurdex | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-11-05 | Eylea Hd | $39 |
| Abbvie | Meals · 2025-10-23 | Ozurdex | $25 |
| Abbvie | Meals · 2025-10-03 | Ozurdex | $26 |
| Abbvie | Meals · 2025-09-20 | Ozurdex | $24 |
| Abbvie | Meals · 2025-08-28 | Ozurdex | $30 |
| Apellis Pharmaceuticals | Meals · 2025-08-22 | Syfovre | $109 |
| Abbvie | Meals · 2025-07-31 | Ozurdex | $20 |
| Alcon Vision | Meals · 2025-07-23 | Hydrus Microstent | $69 |
| Apellis Pharmaceuticals | Meals · 2025-06-23 | Syfovre | $157 |
| Abbvie | Meals · 2025-06-05 | Ozurdex | $21 |
| Abbvie | Meals · 2025-06-04 | Ozurdex | $125 |
| Regeneron Healthcare Solutions | Meals · 2025-02-20 | Eylea Hd | $60 |
| Abbvie | Meals · 2025-02-05 | Ozurdex | $10 |
See earlier years (2024)
2024: $324
| Alcon Vision | Clareon | $176 | 3 payments
|
| Alimera Sciences | Yutiq | $127 | 1 payment
|
| Bausch & Lomb Americas | Envista Mx60 Iol | $21 | 1 payment
|
Professional record
- NPI
- 1194345975
- Licence
- CA 195274California A195274: Current · expires 2028-06-30
- Group
- Retina Vitreous Associates Medical Group · USC Care Medical Group Inc
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 14726 Ramona Ave Ste 203, Chino, CA, 91710
- NPI first listed
- 2020-04-21
- NPI last updated
- 2026-07-09
- NPI record certified
- 2026-07-09
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.